Update on 2019 AGM resolution vote, Clinigen Group plc, 2020-05-26

RNS Number : 9661N
Clinigen Group plc
26 May 2020


26 May 2020






Update on 2019 AGM resolution vote


Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, provides an update following the 31.59% of votes against the resolution to re-elect Peter Allen (‘Chairman’) at its Annual General Meeting (‘AGM’) held on 26 November 2019. This update is in accordance with the requirement of Provision 4 of the UK Corporate Governance Code (2018) (the ‘Code’).


Prior to and following the AGM held in November 2019, the Board engaged with the Group’s largest institutional investors and proxy companies, to provide an opportunity for them to share their views on corporate governance and to cover questions more generally.


The question of ‘overboarding’ has increased in prominence over the last year, arising from concerns that Directors may not be able to properly fulfil their duties where they have too many competing commitments to other listed companies. The Board specifically recognises that it is best practice for the Chairman not to be a member of the Audit Committee. With this in mind, along with the Board’s commitment to comply with best practice where possible, Mr Allen has relinquished his position as a member of the Audit and Risk Committee with immediate effect. He will continue as Chairman of the Nominations Committee and as a member of the Remuneration Committee.


The Group has also noted that Mr Allen will step down as Chairman of the Board of Diurnal Group on 30 June 2020, as announced on 5 March 2020 by Diurnal Group plc.


The Board is confident that Mr Allen discharges his obligations as Chairman notwithstanding his other obligations and believes that Mr Allen provides effective leadership and manages Board meetings extremely well. Further, the Board finds the additional insight gained by his participation on other Boards to be of enormous benefit.


The Group will continue to engage with shareholders on this topic and will set out further details within the Group’s 2020 Annual Report and Accounts.


Contact details

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Chief Executive Officer

Nick Keher, Chief Financial Officer

Matt Parrish, Head of Investor Relations

J.P.Morgan Cazenove – Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

RBC Capital Markets – Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Phillip Marriage

Email: [email protected]


Notes to Editors


About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.


Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.


For more information on Clinigen, please visit www.clinigengroup.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.




Leave a Reply

Your email address will not be published.